Welcome to our dedicated page for ASLAN Pharmaceuticals American Depositary Shares news (Ticker: ASLN), a resource for investors and traders seeking the latest updates and insights on ASLAN Pharmaceuticals American Depositary Shares stock.
ASLAN Pharmaceuticals Limited (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company dedicated to developing innovative treatments that transform the lives of patients. Headquartered in Singapore with offices in Taiwan and China, ASLAN is tackling high-prevalence diseases in Asia and orphan indications in the United States and Europe.
ASLAN's strategic portfolio includes four product candidates targeting validated growth pathways, novel immune checkpoints, and cancer metabolic pathways. Their flagship projects are eblasakimab, a first-in-class antibody targeting the IL-13 receptor for moderate-to-severe atopic dermatitis (AD), and farudodstat, an oral inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) for alopecia areata (AA).
In recent developments, eblasakimab has shown promising results in a Phase 2b, dose-ranging study, achieving significant improvements in AD patients. Concurrently, farudodstat is progressing through a Phase 2a, proof-of-concept trial with interim results expected soon.
ASLAN actively collaborates with industry leaders such as Array BioPharma, Bristol-Myers Squibb, Almirall, and CSL to bolster their research and development efforts. The company's strategic alliances aim to leverage combined expertise for enhanced therapeutic outcomes.
On March 12, 2024, ASLAN announced a definitive agreement to sell 5,000,000 American Depositary Shares (ADSs) at $1.00 per ADS in a direct offering, with warrants issued in a concurrent private placement. The proceeds will fund ongoing R&D activities and general corporate purposes.
Despite financial challenges, including a reported deficit of $13.3 million in stockholders’ equity for 2023, ASLAN is committed to regaining compliance with Nasdaq listing requirements. This determination is underscored by their continuous efforts to advance their clinical pipeline and explore new research collaborations, such as their recent agreement with Zenyaku Kogyo Co., Ltd.
ASLAN's proactive approach, supported by a solid management team with deep global and regional expertise, aims to generate significant clinical advances and commercial opportunities. For more information, visit the ASLAN website or follow them on LinkedIn.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has appointed Dr. Lawrence Eichenfield as chair of its Scientific Advisory Board, focusing on advancing ASLAN004 for atopic dermatitis and allergic disease. Dr. Eichenfield is an expert in dermatology, with over 400 publications. Dr. Eric Simpson joins him on the board, enhancing ASLAN's clinical expertise. The company is poised to initiate its Phase 2b study of ASLAN004, awaiting new unblinded data soon. These appointments aim to leverage their extensive knowledge to meet the significant unmet needs in dermatological care.
ASLAN Pharmaceuticals (Nasdaq:ASLN), a biopharmaceutical company focused on immunology, announced that CEO Dr. Carl Firth will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The conference runs from September 13-15, 2021. An on-demand recording of Dr. Firth's presentation will be available on September 13 at 7:00 AM ET on ASLAN’s Investor Relations website. ASLAN is developing innovative treatments, including ASLAN004 for atopic dermatitis and ASLAN003 for autoimmune diseases.
ASLAN Pharmaceuticals (Nasdaq: ASLN) has completed recruitment for the expansion cohort of its Multiple Ascending Dose (MAD) trial for ASLAN004, aimed at treating moderate-to-severe atopic dermatitis. Topline data from 27 additional patients is expected by the end of Q3 2021. Financial results for Q2 2021 show a net loss of $5.5 million, up from $4.0 million in Q2 2020, with cash and equivalents at $94.1 million. The company secured a $45 million loan facility to support clinical developments, including a Phase 2b trial for ASLAN004 and a Phase 2 trial for ASLAN003.
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that Dr. Carl Firth, CEO, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 09:00 am ET. The event runs from August 9 to August 10, 2021. ASLAN is focused on developing innovative treatments for patients with clinical-stage immunology. The company is advancing ASLAN004, targeting IL-13 for atopic dermatitis, and ASLAN003, an oral inhibitor for autoimmune diseases. More details are available on their website.
ASLAN Pharmaceuticals announces a secured loan facility of up to $45 million from K2 HealthVentures to support its clinical program for ASLAN003, targeting autoimmune gastrointestinal and skin diseases. The initial $20 million will fund the project, with $25 million contingent upon certain conditions. The financing extends ASLAN’s cash runway into late 2023 and allows repayment of existing loans. Dr. Carl Firth expresses optimism about enhancing clinical activities, while K2HV is aligned with ASLAN's goals for innovative treatments.
ASLAN Pharmaceuticals (Nasdaq:ASLN) announced that CEO Dr. Carl Firth will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:30 am ET. The conference runs from June 1-4, 2021. Investors can access a live webcast of the chat via a link provided in the PR or through ASLAN's Investor Relations section on their website. This event highlights ASLAN's commitment to developing innovative treatments in immunology, particularly ASLAN004 for atopic dermatitis and ASLAN003 for autoimmune diseases.
ASLAN Pharmaceuticals (Nasdaq:ASLN) reported financial results for Q1 2021, highlighting a net loss of $6.7 million, up from $3.0 million in Q1 2020. Cash reserves increased significantly to $100.8 million following financing activities. The company is advancing its Phase 1 trial for ASLAN004, targeting atopic dermatitis, with additional patient enrollment expected and topline data by Q3 2021. Upcoming milestones include the initiation of a Phase 2b trial for ASLAN004 in the second half of 2021. Dr. Karen Veverka and Joseph Suttner join the senior management team to bolster clinical operations.
ASLAN Pharmaceuticals announced a poster presentation for ASLAN004 at the 2021 Society for Investigative Dermatology meeting, scheduled for May 6, 2021. The study focuses on the safety and tolerability of ASLAN004, a novel monoclonal antibody targeting IL-13 receptor α1, with implications for treating atopic dermatitis and asthma. The presentation will highlight findings from an earlier Single Ascending Dose study, supporting the ongoing clinical development plans for ASLAN004. The poster will be available online post-presentation.
ASLAN Pharmaceuticals (ASLN) announced its fourth quarter and full year 2020 financial results, reporting a net loss of $5.7 million for Q4 2020, significantly down from $29.6 million in Q4 2019. The company is progressing with ASLAN004 for moderate to severe atopic dermatitis, with topline data expected by Q3 2021. It raised approximately $69 million in March 2021 and reported $14.3 million in cash as of December 31, 2020. ASLAN is on track to initiate a Phase 2b study for ASLAN004 in the latter half of 2021, indicating a strong financial position to support ongoing development activities.
ASLAN Pharmaceuticals (Nasdaq: ASLN) announced the appointment of Kathleen M. Metters, PhD, as an independent director on March 18, 2021. Dr. Metters brings over 30 years of expertise in developing therapies for chronic and autoimmune diseases. She previously served as CEO of Lycera Corp and held leadership roles at Merck & Co. Additionally, Damien Lim has transitioned off the board after 10 years. Chairman Andrew Howden expressed confidence in Dr. Metters’ ability to enhance ASLAN's clinical programs and its strategic pivot to the US market.
FAQ
What is the current stock price of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is the market cap of ASLAN Pharmaceuticals American Depositary Shares (ASLN)?
What is ASLAN Pharmaceuticals' focus?
What are ASLAN Pharmaceuticals' main products?
Where is ASLAN Pharmaceuticals headquartered?
Who are ASLAN Pharmaceuticals’ partners?
What recent financial activities has ASLAN Pharmaceuticals undertaken?
What clinical advancements has ASLAN Pharmaceuticals made recently?
How is ASLAN Pharmaceuticals addressing its financial challenges?
What is the purpose of ASLAN Pharmaceuticals’ recent collaboration with Zenyaku Kogyo?
What is eblasakimab?
What are the potential benefits of farudodstat?
